Page 2
-
Enlaza gets JP Morgan, Regeneron backing for covalent biologics
The funds will help the cancer-focused startup Enlaza bring several candidates toward human testing in the next few years, its CEO said.
-
Deciphera to sell for $2.4B, adding to upswing in biopharma M&A
For Japan-based Ono Pharmaceutical, buying Deciphera offers a way to build out in cancer research as well as get a stronger foothold in the U.S. and European markets.
-
Bristol Myers to cut 6% of workforce, trim drug pipeline
The layoffs will impact some 2,200 employees, the company said, as it repositions ahead of looming patent expirations for top-selling products.
Updated April 25, 2024 -
FDA finalizes lab developed test rule over industry opposition
Risks associated with the tests have increased, requiring greater oversight to protect patients, the agency contends.
-
Prime gets FDA green light to begin first trial test of ‘prime editing’
The company will soon start a Phase 1/2 study of its treatment for chronic granulomatous disease, a milestone for the search-and-replace gene editing technology.
-
Emerging biotech
Repertoire pivot pays dividends with Bristol Myers deal
The alliance validates the new direction pursued by Repertoire, a startup that cut staff and switched CEOs in 2022 after research on personalized cell therapies disappointed.
-
Pfizer hemophilia gene therapy arrives in US to uncertain future
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.
-
AbbVie tries to reassure investors on Humira biosimilar threat
Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.
-
BioMarin drops drug programs in pipeline cull
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
-
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
-
Gene editing
Regeneron expands in gene editing with Mammoth deal
“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.
-
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.
-
Moderna turns to AI to change how its employees work
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.
-
Biogen sees ‘encouraging’ trends for postpartum depression drug
First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue.
-
CureVac to cut costs in restructuring
The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.
-
Emerging biotech
Endeavor pulls in $132M to back cancer, lung disease drugs
Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers.
Updated April 24, 2024 -
New Alzheimer's drugs
Biogen to invest more in launch of Alzheimer’s drug Leqembi
Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.
-
Novartis raises forecasts as top drug sales beat Wall Street estimates
Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.
-
Former Bristol Myers CEO tapped as Novartis’ next board chair
Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.
-
Neurocrine scores surprise win with depression drug
Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.
-
FDA rejects Abeona cell therapy, asks for more manufacturing data
The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.
-
Lilly to buy injectable drug plant in manufacturing ramp-up
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
-
Bristol Myers taps startup to boost cell therapy production
A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of CAR-T treatments for cancer.
-
Pharmas form joint venture to jumpstart Japanese drug research
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
-
Eisai hunts for next Alzheimer’s drug with new research pact
A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.